Effectiveness of Adjunctive Reboxetine on Deficit Symptoms of Schizophrenia
DOI:
https://doi.org/10.61841/2pc1p610Keywords:
schizophrenia;, negative symptom, reboxetine.Abstract
Objective: Deficit syndrome is an important dilemma against social participation of schizophrenic patients. Reboxetine is a norepinephrine reuptake inhibitor (NRI) .Objective of this study was to evaluate its effect on the negative symptoms of schizophrenia.
Method: in a 12-week randomized placebo-controlled trial, reboxetine was compared with placebo, as an ad- junctive to haloperidol (5 mg), for treatment of 50 patients meeting DSM-IV-TR criteria for schizophrenia. In this respect, Scale for Assessment of Negative Symptoms (SANS) was used as the primary outcome measure. Treatment efficacy was analyzed by t test, Split-plot (Mixed) and repeated –measures analysis of variance (ANOVA).
Result: The primary finding of this trial was a significant reduction in mean total scores of SANS in the re- boxetine group, in comparison with the placebo group, at the end of the 12th week (P <0.0001). As well, in the experiment group, all of the sub-scales of SANS demonstrated considerable improvement. A trivial escalation in mean total scores of SAPS also was evident in the later group. Effect Size (ES) analysis too at the end of the trial, pointed to a large improvement with reboxetine.
Conclusion: reboxetine, as adjuvant to haloperidol, may cause a favorable outcome on behalf of improvement of deficit symptoms of schizophrenia.
Downloads
References
Carpenter W. Pharmacotherapy of schizophrenia, Negative symptoms. (Sup) Am J Psychiatr 1997 154:123.
Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E: A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995 117:417-423.
M. Poyurovsky, I. Isaacs, C. Fuchs, M. Schneidman, S. Faragian, R. Weizman et al.: Attenuation of olanza- pine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study. Am J Psychiatry 160 (2003), pp. 297–302.
Raedler TJ, Jahn H, Arlt J, Kiefer F, Schick M, Naber D, Wiedemann K: Adjunctive use of reboxetine in schizophrenia. Eur Psychiatry. 2004 Sep;19(6):366-9.
Schutz G, Berk M: Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2001 Sep; 16(5):275-8.
Silver H, Nassar A: Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992 31:698-704.
Taylor D, Paton C, Kapur S: The Maudsley Prescribing Guidelines in sychiatry;Blackwell Publishing. 11th Edition, 2012.
Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-gly- coprotein by newer antidepressants. Journal of Pharmacology & Experimental Therapeutics,2003, 305 (1): 197–204.
Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, Di Rosa AE, Meduri M: The effect of mir- tazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2004 Mar;19(2):71-6
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
